Abstract Number: 203 • 2016 ACR/ARHP Annual Meeting
Allopurinol Dose Escalation and Mortality Among Patients with Gout: A National Propensity-Matched Cohort Study
Allopurinol Dose Escalation and Mortality among Patients with Gout: A National Propensity-Matched Cohort Study Background/Purpose: Numerous epidemiologic studies show that hyperuricemia and gout are associated…Abstract Number: 204 • 2016 ACR/ARHP Annual Meeting
The Safety and Efficacy of Allopurinol Dose Escalation in People with Gout, a Randomised Controlled Trial
Background/Purpose: Allopurinol is the most widely used urate lowering therapy. Many patients on allopurinol fail to achieve target serum urate (SU), in part due to…Abstract Number: 207 • 2016 ACR/ARHP Annual Meeting
Integrated Safety of Lesinurad, a Novel Uric Acid Reabsorption Inhibitor for the Treatment of Gout
Background/Purpose: Lesinurad is a selective uric acid reabsorption inhibitor recently approved at 200 mg daily in combination with a xanthine oxidase inhibitor (XOI) for treatment…Abstract Number: 208 • 2016 ACR/ARHP Annual Meeting
Examination of Serum Uric Acid (sUA) Lowering and Safety with Extended Lesinurad + Allopurinol Treatment in Subjects with Gout
Background/Purpose: Two replicate, randomized, core Phase III trials (CLEAR 1 & 2) reported significantly more subjects treated with lesinurad 200 mg (LESU200) or 400 mg…Abstract Number: 209 • 2016 ACR/ARHP Annual Meeting
Clinical Response of Tophus and Flares to Extended Use of Lesinurad in Combination with a Xanthine Oxidase Inhibitor in Patients with Gout
Background/Purpose: Three randomized, double-blind, Phase III trials reported that greater proportions of patients treated with lesinurad 200 mg (LESU200) or 400 mg (LESU400), combined with…Abstract Number: 210 • 2016 ACR/ARHP Annual Meeting
Skin Events with Febuxostat in Gout Patients and Previous Skin Reactions to Allopurinol. a Retrospective Review
Background/Purpose: Allopurinol is the most used urate-lowering agent for patients with gout, but around 10% of patients show intolerance to this drug, often at skin,…Abstract Number: 212 • 2016 ACR/ARHP Annual Meeting
Pegloticase Provides Clinical Benefit in Patients with Chronic Refractory Gout Who Did Not Meet the Clinical Trial Biochemical Definition of Response
Background/Purpose: Pegloticase is a recombinant uricase conjugated to polyethylene glycol approved for the treatment of chronic refractory gout refractory. The pivotal clinical trials for pegloticase…Abstract Number: 215 • 2016 ACR/ARHP Annual Meeting
Anakinra Is Effective and Well Tolerated in Medically Complex Patients Including Transplant Recipients with Gout
Background/Purpose: Anakinra is a biologic response modifier that competitively antagonizes the biologic effects of interleukin-1β. Conventional treatments for the inflammatory response to acute gout are…Abstract Number: 216 • 2016 ACR/ARHP Annual Meeting
Colchicine Prescribing As a Parameter for QA/QI Process in Gout Care
Background/Purpose: Because of the large increase in the price of colchicine with the FDA granted market exclusivity the Pharmacy at the Mpls VA HCS asked…Abstract Number: 217 • 2016 ACR/ARHP Annual Meeting
The Effect of Regular Treatment on Disability in a Cohort of Patients with Gout.
Background/Purpose: The severity of gout is often associated with poor patient compliance and sub-optimal medical treatment. Our objective was to determine the prevalence, characteristics, and…Abstract Number: 219 • 2016 ACR/ARHP Annual Meeting
Presence of Monosodium Urate Crystals By Dual-Energy Computed Tomography in Gout Patients Treated with Allopurinol
Background/Purpose: Chronic hyperuricemia predisposes to deposition of monosodium urate (MSU) crystals in musculoskeletal and other tissues, causing chronic inflammation, acute gout flares, joint damage, and…Abstract Number: 220 • 2016 ACR/ARHP Annual Meeting
Urate Lowering Therapy Regresses Ultrasound Abnormalities in Gout
Background/Purpose: Detection of double contour sign (DCS) and hyperechoic aggregates (HAG) is a reliable method in detecting urate crystal deposition by ultrasound (US) which has…Abstract Number: 221 • 2016 ACR/ARHP Annual Meeting
Ultrasound in Gout: The Clinical Application
Background/Purpose: The utility of ultrasound (US) in aiding the diagnosis of gout has been well established. The latest 2015 gout classification criteria have included the…Abstract Number: 223 • 2016 ACR/ARHP Annual Meeting
Clinical Predictors of Acute Gout Flares within Hospitalized Patients at a Tertiary Care Center in New York
Background/Purpose: Gout is the most prevalent inflammatory arthritis worldwide. Within the healthcare setting, gout flares contribute to substantial morbidity and complicated hospital stays. Identifying risk…Abstract Number: 224 • 2016 ACR/ARHP Annual Meeting
Patient Perception of Gout Flares As a Measure of Outcome: Results from an International Study
Patient Perception of Gout Flares as a Measure of Outcome: Results from an International Study Background/Purpose: Attacks (flares) are one of the primary manifestations of…
Simple Search Results
Didn't find what you were looking for? Try the Advanced Search »
Didn't find what you were looking for? Try the Advanced Search »